HEMATOLOGY

Matthew Ulrickson, MD, discusses a patient case of BPDCN, emphasizing the importance of recognizing and treating this rare disease, exploring various treatment options, and highlighting the evolving prognosis.

With a partial clinical hold in place, patient enrollment must halt in the phase 1 NX-2127-001 trial.

In the fourth article of this series, Amer Zeidan, MBBS, MHS, reviews recent data in lower-risk myelodysplastic syndrome and discusses the evolving treatment landscape.

Allogeneic transplant is, today, a curative therapy for a variety of blood cancers, including many cases of acute monocytic leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes.

Hetty Carraway, MD, MBA, discusses treatment with tagraxofusp and allogeneic stem cell transplant for patients with blastic plasmacytoid dendritic cell neoplasm.

In an interview with Targeted Oncology, Courtney DiNardo, MD, MSCE, discussed what oncologists should know about ivosidenib and the drug’s potential in treating hematologic malignancies.

A study published in the Journal of the American College of Cardiology found that chimeric antigen receptor T-cell therapy was associated with fewer major cardiac events than previously thought. 

Ivosidenib tablets have received FDA approval for the treatment of adult patients with relapsed/refractory myelodysplastic syndromes with a susceptible IDH1 mutation.

During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, asked physicians about their experiences with patients with hematological malignancies with skin manifestations, and how to diagnose and work up these patients. This is the first of 2 articles based on this event.

A novel CD20xCD3 bispecific antibody showed promising safety and preliminary antitumor activity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Dan T. Vogl, MD, MSCE, discusses the mechanism of action of modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.

James Foran, MD, offers valuable insights on recognizing and treating blastic plasmacytoid dendritic cell neoplasm, emphasizing the importance of early diagnosis, collaboration with specialists, and staying informed about therapeutic advances.

Expert perspectives on the sequencing of treatment options for blastic plasmacytoid dendritic cell neoplasm, considering patient age, response to tagraxofusp, venetoclax-based therapies, clinical trials, and future possibilities for targeted agents.

Expert perspectives on the sequencing of treatment options for blastic plasmacytoid dendritic cell neoplasm, considering patient age, response to tagraxofusp, venetoclax-based therapies, clinical trials, and future possibilities for targeted agents.

A key opinion leader identifies the clinical manifestations and diagnostic markers of blastic plasmacytoid dendritic cell neoplasm, shedding light on its presentation and diagnostic significance in real-world medical settings.

A review of diagnostic challenges and comprehensive workup, including CD markers, cytogenetics, and next-generation sequencing, for patients with blastic plasmacytoid dendritic cell neoplasm, a rare and unique acute leukemia.

Expert James Foran, MD, discusses the challenging case of an 87-year-old patient diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), its diagnosis, and treatment options, highlighting the unique considerations for elderly individuals.

While there was no significant difference in overall survival between the daratumumab and control groups, safety profile results and follow-up data support daratumumab’s continued evaluation in relapsed/refractory multiple myeloma.

Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.

Bexmarilimab shows encouraging results when combined with standard of care treatments for patients with acute myeloid leukemia and myelodysplastic syndromes.

In an interview with Targeted Oncology, Justin Taylor, MD, discussed early research on NX-2127, a BTK degrader being evaluated for the treatment of chronic lymphocytic leukemia.

C. Ola Landgren, MD, PhD, discussed the ASCENT trial and his predictions for future developments in the myeloma space.

During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, explained the research he and others conducted leading to the development of tagraxofusp-erzs to treat patients with blastic plasmacytoid dendritic cell neoplasm.

Amer Zeidan, MBBS, discusses the rationale of studying imetelstat in the phase 3 IMerge trial in patients with lower-risk myelodysplastic syndrome.

Closing the program on chronic graft versus host disease, the panelists share what they are most looking forward to in the space.

Evolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.

In an interview with Targeted Oncology, Amer Zeidan, MBBS, discussed the IMerge study and next steps for imetelstat for patients with lower-risk MDS.

In the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.

Uwe Platzbecker, MD, discussed findings from recent phase 3 trials and their clinical implications for daily care in patients with lower-risk myelodysplastic neoplasms.

An analysis examined survival outcomes in several subgroups of patients with hematologic cancers compared with the overall population.